Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ digital
    • Subscribe to CMAJ print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Letters

Fundamental problem with opioid trials for chronic pain

Tushar Mehta
CMAJ April 24, 2007 176 (9) 1307-1308; DOI: https://doi.org/10.1503/cmaj.1060140
Tushar Mehta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2007 Canadian Medical Association or its licensors

One problem with research on opioids for noncancer pain, in addition to those outlined by Andrea Furlan and associates,1 is the cognitive effect of these drugs, which makes it difficult to compare them with either placebo or active placebo such as NSAIDs. Even a nominal dose of opioids will improve mood through a euphoric effect. Tolerance develops such that the patient experiences intermittent withdrawal symptoms and smaller euphoric effects with trough and peak drug levels.

Under such conditions, patients will generally endorse the benefit of opioids for chronic noncancer pain. Euphoria is associated with pain relief and a greater sense of well-being, and the dysphoria and pain of withdrawal are associated with worsening chronic noncancer pain.

Further, it is often difficult for patients to recall how bad their pain was before they started treatment with opioids, and people taking opioids for chronic noncancer pain are likely to report an improvement in their overall condition even if they are worse off with the peak and trough effect of the opioid regimen. Perhaps they think that going without opioids altogether would feel like a trough: a state of withdrawal.

How else could research be done in this area? Delivering opioids via pumps that provide continuous infusions or fentanyl patches might overcome some of these problems. The dose would have to be titrated gradually, and a suitable placebo would be necessary. In trials comparing opioids in pill form with active placebo, perhaps the active placebo should contain one ingredient that gives nociceptive relief (e.g., NSAIDs) and a second ingredient that produces a calming but euphoric effect (e.g., a benzodiazepine such as lorazepam).

In traditional trials comparing oral opioids with placebo or NSAIDs, objective and detailed assessments of level of functioning and overall quality of life are better primary outcomes than pain. Participants' functioning, quality of life and pain should also be measured at a single point in time rather than being compared with baseline values.

REFERENCE

  1. 1.↵
    Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 2006;174(11):1589-94.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 176 (9)
CMAJ
Vol. 176, Issue 9
24 Apr 2007
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Fundamental problem with opioid trials for chronic pain
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Fundamental problem with opioid trials for chronic pain
Tushar Mehta
CMAJ Apr 2007, 176 (9) 1307-1308; DOI: 10.1503/cmaj.1060140

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Fundamental problem with opioid trials for chronic pain
Tushar Mehta
CMAJ Apr 2007, 176 (9) 1307-1308; DOI: 10.1503/cmaj.1060140
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • REFERENCE
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • The authors respond to letters on using prescribed psychostimulants to treat stimulant use disorder
  • Vigilance needed with methamphetamine-associated psychosis
  • Critical examination of incorporating prescription psychostimulants into the continuum of care for people with stimulant use disorder in Canada
Show more Letters

Similar Articles

Collections

  • Topics
    • Drugs: central nervous system (not psychiatric)
    • Pain

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire